Molecular Studies to Identify Mechanisms That Underlie Symptom Improvement in Microbiota Transfer Therapy Patients
Abstract
The purpose of this study is to perform molecular analysis (transcriptomic and metabolomic assays) on samples (whole blood, serum, and stool) derived from 84 adults with autism spectrum disorder (ASD) undergoing microbiota transfer therapy (MTT), and 84 adult controls, from an on-going CDMRP-funded clinical trial (James Adams, PI; Arizona State University) to identify mechanisms that underlie symptom improvement following MTT. Due to the onset of the coronavirus pandemic, recruitment at the ASU site has been severely curtailed since March2020, and so sample collection and transfer to me has been limited to a portion of the initial 35 ASD sample sets, and 11 control sample sets. Because these samples need to be assayed in batches, although we have begun sample processing, we have not yet begun the molecular assays. We will get the assays underway in the Winter of this year (2023) and have requested, and been granted, a no-cost extension to complete the work in 2024.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2023
- Accession Number
- AD1225998
Entities
People
- Stephen J. Walker
Organizations
- Wake Forest University